Your browser is no longer supported. Please, upgrade your browser.
Settings
ADXS [NASD]
Advaxis, Inc.
Index- P/E- EPS (ttm)-0.60 Insider Own0.09% Shs Outstand109.82M Perf Week12.96%
Market Cap48.68M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float62.61M Perf Month84.79%
Income-30.20M PEG- EPS next Q- Inst Own17.70% Short Float0.39% Perf Quarter45.65%
Sales0.30M P/S162.28 EPS this Y94.40% Inst Trans- Short Ratio0.03 Perf Half Y8.68%
Book/sh0.51 P/B1.20 EPS next Y- ROA-66.40% Target Price- Perf Year-52.34%
Cash/sh0.30 P/C2.05 EPS next 5Y- ROE-81.60% 52W Range0.26 - 1.35 Perf YTD74.94%
Dividend- P/FCF- EPS past 5Y40.40% ROI-49.70% 52W High-54.81% Beta3.13
Dividend %- Quick Ratio8.40 Sales past 5Y83.60% Gross Margin- 52W Low131.15% ATR0.07
Employees35 Current Ratio8.40 Sales Q/Q- Oper. Margin- RSI (14)64.16 Volatility16.06% 14.78%
OptionableNo Debt/Eq0.00 EPS Q/Q90.50% Profit Margin- Rel Volume0.92 Prev Close0.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume8.71M Price0.61
Recom2.00 SMA2038.59% SMA5058.31% SMA20017.83% Volume7,994,475 Change-4.06%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Dec-22-20 01:42PM  
Dec-16-20 01:05PM  
08:00AM  
Dec-13-20 11:15PM  
Nov-27-20 12:07PM  
11:01AM  
Nov-24-20 08:30AM  
Nov-23-20 04:05PM  
Nov-09-20 08:01AM  
Oct-26-20 08:00AM  
Oct-15-20 08:00AM  
Sep-29-20 08:30AM  
Sep-24-20 08:00AM  
Sep-10-20 08:00AM  
Sep-04-20 04:30PM  
Aug-31-20 05:00PM  
Aug-27-20 08:00AM  
Aug-05-20 09:00AM  
Aug-03-20 09:31PM  
08:00AM  
Jun-23-20 08:00AM  
Jun-17-20 06:25AM  
Jun-11-20 08:00AM  
Jun-01-20 08:00AM  
May-14-20 08:00AM  
Mar-13-20 09:00AM  
Mar-03-20 04:01PM  
Feb-27-20 09:00AM  
Feb-20-20 08:00AM  
Feb-16-20 03:03PM  
Feb-13-20 08:00AM  
Feb-11-20 08:00AM  
Jan-30-20 09:23AM  
Jan-21-20 08:30AM  
Jan-07-20 08:00AM  
Dec-22-19 05:08PM  
Dec-20-19 08:00AM  
05:04AM  
Dec-04-19 08:00AM  
Dec-03-19 08:00AM  
Oct-24-19 09:00AM  
Oct-10-19 08:00AM  
Oct-07-19 08:00AM  
Sep-19-19 06:36AM  
Sep-10-19 07:36AM  
Sep-09-19 08:00AM  
Aug-22-19 08:00AM  
Aug-12-19 06:30AM  
Jul-25-19 11:30AM  
Jul-24-19 07:08AM  
Jul-23-19 08:30AM  
Jul-15-19 08:00AM  
Jun-27-19 06:50AM  
Jun-21-19 10:14AM  
Jun-11-19 09:00AM  
Jun-10-19 04:05PM  
Jun-04-19 08:00AM  
May-25-19 09:48AM  
May-15-19 10:25AM  
08:00AM  
May-14-19 09:00AM  
May-13-19 03:00PM  
May-07-19 09:00AM  
Apr-18-19 05:45PM  
Apr-16-19 10:54AM  
Apr-10-19 08:43AM  
Apr-08-19 09:30AM  
Apr-03-19 04:31PM  
08:19AM  
07:44AM  
07:30AM  
Apr-02-19 04:05PM  
09:44AM  
Apr-01-19 04:31PM  
03:18PM  
02:27PM  
12:20PM  
12:11PM  
08:00AM  
Mar-30-19 09:32AM  
Mar-29-19 03:00PM  
Mar-28-19 01:00PM  
10:41AM  
Mar-27-19 10:54AM  
Mar-25-19 09:25AM  
08:00AM  
Mar-22-19 09:30AM  
Mar-13-19 03:00PM  
08:45AM  
Mar-12-19 08:13AM  
08:00AM  
Mar-11-19 08:00AM  
Feb-20-19 10:51AM  
Feb-14-19 08:30AM  
Feb-12-19 01:10PM  
Feb-06-19 08:30AM  
Jan-31-19 12:34PM  
Jan-30-19 07:35AM  
Jan-28-19 08:05AM  
Jan-25-19 08:05AM  
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
APPEL RONIDirectorMar 13Sale0.552,4011,32110,476Mar 16 05:00 PM
APPEL RONIDirectorMar 12Sale0.5820011612,877Mar 16 05:00 PM
APPEL RONIDirectorMar 11Sale0.6739926713,077Mar 16 05:00 PM